Early Evaluation of Immunotherapy Response in Lymphoma Patients by 18F-FDG PET/CT: A Literature Overview

被引：18

作者：

Ferrari, Cristina ^{[1
]}

Maggialetti, Nicola ^{[2
]}

Masi, Tamara ^{[1
]}

Nappi, Anna Giulia ^{[1
]}

Santo, Giulia ^{[1
]}

Niccoli Asabella, Artor ^{[3
]}

Rubini, Giuseppe ^{[1
]}

机构：

[1] Univ Aldo Moro, DIM, Sect Nucl Med, Piazza Giulio Cesare 11, I-70124 Bari, Italy

[2] Univ Aldo Moro, DSMBNOS, Sect Radiodiagnost, Piazza Giulio Cesare 11, I-70124 Bari, Italy

[3] AOU Policlin A Perrino, Nucl Med Unit, I-72100 Brindisi, Italy

来源：

JOURNAL OF PERSONALIZED MEDICINE | 2021年 / 11卷 / 03期

关键词：

immunotherapy; 18F-FDG PET/CT; Hodgkin lymphoma; Non Hodgkin lymphoma; immuno-checkpoint inhibitors; CAR-T cell therapy; RECEPTOR T-CELLS; HODGKIN LYMPHOMA; TUMOR MICROENVIRONMENT; CHECKPOINT BLOCKADE; PD-1; BLOCKADE; F-18-FDG PET; NIVOLUMAB; THERAPY; RADIOTHERAPY; CT;

D O I：

10.3390/jpm11030217

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

Immunotherapy is a promising therapeutic strategy both for solid and hematologic tumors, such as in Hodgkin (HL) and non-Hodgkin lymphoma (NHL). In particular, immune-checkpoint inhibitors, such as nivolumab and pembrolizumab, are increasingly used for the treatment of refractory/relapsed HL. At the same time, evidence of chimeric antigen receptor (CAR)-T-cell immunotherapy efficacy mostly in NHL is growing. In this setting, the challenge is to identify an appropriate imaging method to evaluate immunotherapy response. The role of 18F-Fluorodeoxyglucose (18F-FDG) positron-emission tomography/computed tomography (PET/CT), especially in early evaluation, is under investigation in order to guide therapeutic strategies, taking into account the possible atypical responses (hyperprogression and pseudoprogression) and immune-related adverse events that could appear on PET images. Herein, we aimed to present a critical overview about the role of 18F-FDG PET/CT in evaluating treatment response to immunotherapy in lymphoma patients.

引用

页数：17

共 90 条

[21] Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087 [J].

Chen, Robert ;

Zinzani, Pier Luigi ;

Lee, Hun Ju ;

Armand, Philippe ;

Johnson, Nathalie A. ;

Brice, Pauline ;

Radford, John ;

Ribrag, Vincent ;

Molin, Daniel ;

Vassilakopoulos, Theodoros P. ;

Tomita, Akihiro ;

von Tresckow, Bastian ;

Shipp, Margaret A. ;

Lin, Jianxin ;

Kim, Eunhee ;

Nahar, Akash ;

Balakumaran, Arun ;

Moskowitz, Craig H. .

BLOOD, 2019, 134 (14) :1144-1153

[22] Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma [J].

Chen, Robert ;

Zinzani, Pier Luigi ;

Fanale, Michelle A. ;

Armand, Philippe ;

Johnson, Nathalie A. ;

Brice, Pauline ;

Radford, John ;

Ribrag, Vincent ;

Molin, Daniel ;

Vassilakopoulos, Theodoros P. ;

Tomita, Akihiro ;

von Tresckow, Bastian ;

Shipp, Margaret A. ;

Zhang, Yinghua ;

Ricart, Alejandro D. ;

Balakumaran, Arun ;

Moskowitz, Craig H. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (19) :2125-+

[23] Understanding the Mechanisms of Resistance to CAR T-Cell Therapy in Malignancies [J].

Cheng, Jiali ;

Zhao, Lei ;

Zhang, Yuanyuan ;

Qin, Yun ;

Guan, Yuqi ;

Zhang, Tong ;

Liu, Chaohong ;

Zhou, Jianfeng .

FRONTIERS IN ONCOLOGY, 2019, 9

[24] Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy [J].

Cheson, Bruce D. ;

Ansell, Stephen ;

Schwartz, Larry ;

Gordon, Leo I. ;

Advani, Ranjana ;

Jacene, Heather A. ;

Hoos, Axel ;

Barrington, Sally F. ;

Armand, Philippe .

BLOOD, 2016, 128 (21) :2489-2496

[25] Reassessing Patterns of Response to Immunotherapy with PET: From Morphology to Metabolism [J].

Costa, Larissa B. ;

Queiroz, Marcelo A. ;

Barbosa, Felipe G. ;

Nunes, Rafael F. ;

Zaniboni, Elaine C. ;

Ruiz, Mariana Mazo ;

Jardim, Denis ;

Gomes Marin, Jose Flavio ;

Cerri, Giovanni G. ;

Buchpiguel, Carlos A. .

RADIOGRAPHICS, 2021, 41 (01) :120-143

[26] Immunotherapy by Immune Checkpoint Inhibitors and Nuclear Medicine Imaging: Current and Future Applications [J].

Decazes, Pierre ;

Bohn, Pierre .

CANCERS, 2020, 12 (02)

[27] Unconventional immune-related phenomena observed using 18F-FDG PET/CT in Hodgkin lymphoma treated with anti PD-1 monoclonal antibodies [J].

Dercle, Laurent ;

Mokrane, Fatima-Zohra ;

de Colella, Jean Marc Schiano ;

Stamatoullas, Apasia ;

Morschhauser, Franck ;

Brice, Pauline ;

Ghesquieres, Herve ;

Casasnovas, Olivier ;

Chen, Aiping ;

Manson, Guillaume ;

Houot, Roch .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (06) :1391-1392

[28] Kinetics and nadir of responses to immune checkpoint blockade by anti-PD1 in patients with classical Hodgkin lymphoma [J].

Dercle, Laurent ;

Ammari, Samy ;

Seban, Romain-David ;

Schwartz, Lawrence H. ;

Houot, Roch ;

Labaied, Nizar ;

Mokrane, Fatima-Zohra ;

Lazarovici, Julien ;

Danu, Alina ;

Marabelle, Aurelien ;

Ribrag, Vincent ;

Michot, Jean-Marie .

EUROPEAN JOURNAL OF CANCER, 2018, 91 :136-144

[29] 18F-FDG PET and CT Scans Detect New Imaging Patterns of Response and Progression in Patients with Hodgkin Lymphoma Treated by Anti-Programmed Death 1 Immune Checkpoint Inhibitor [J].

Dercle, Laurent ;

Seban, Romain-David ;

Lazarovici, Julien ;

Schwartz, Lawrence H. ;

Houot, Roch ;

Ammari, Samy ;

Danu, Alina ;

Edeline, Veronique ;

Marabelle, Aurelien ;

Ribrag, Vincent ;

Michot, Jean-Marie .

JOURNAL OF NUCLEAR MEDICINE, 2018, 59 (01) :15-24

[30]

Derlin T., 2020, ANN NUCL MED, V35, P1007

← 1 2 3 4 5 6 7 8 9 →